

CURRICULUM VITAE

Emily Jane Box, MD

ISN Headquarters:

DJL Clinical Research, PLLC

431 N Wendover Rd

Charlotte, NC 28211

P: 704-247-9179 F: 704-247-9178

jane.box@djlrsearch.com

Site Affiliations:

Metrolina Neurological Research Institute

1665 Herlong Ct, Suite B

Rock Hill, SC 29732

Darst Dermatology

11301 Golf Links Drive North, Suite 203

Charlotte, NC 28277

Oncology Specialists of Charlotte

2711 Randolph Road, Suite 400

Charlotte, NC 28207

Premier Gynecology & Wellness

2310 Randolph Road, Suite B

Charlotte, NC 28207

V Pain Clinic

410 South Herlong Ave

Rock Hill, SC 29732

Digestive Disease Associates

170 Amendment Ave

Rock Hill, SC 29732

Charlotte Skin & Laser

130 Providence Road

Charlotte, NC 28207

Integrative Rheumatology

10826 Mallard Creek Road, Suite 100

Charlotte, NC 28262

Dermatology Specialists of Charlotte

8936 Blakeney Professional Drive

Charlotte, NC 28277

Audiology & Hearing Services of Charlotte

11121 Carmel Commons Blvd, Suite 150

Charlotte, NC 28277

Matthews Internal Medicine

434 N Trade Street, Suite 104

Matthews, NC 28105

Immunocarolina

14135 Ballantyne Corporate Place, Suite 225

Charlotte, NC 28277

Carolina Specialty Care

293 Old Mocksville Road

Statesville, NC 28625

South Charlotte Cardiology

11220 Elm Lane, Suite 200

Charlotte, NC 28277

Board Certification:

1982

1976

1974

Diplomate, Rheumatology

Diplomate, American Board of Internal Medicine

Diplomate, National Board of Medical Examiners

Medical Licensure:

- North Carolina Medical License
- DEA Registration

CURRICULUM VITAE
Emily Jane Box, MD

Education:

1975-1977	Fellowship (Rheumatology) Bowman Gray School of Medicine Winston Salem, North Carolina
1974-1975	Residency (Internal Medicine) North Carolina Baptist Hospital Winston Salem, North Carolina
1973-1974	Internship (Internal Medicine) North Carolina Baptist Hospital Winston Salem, North Carolina
1969-1973	Medical School (MD) Bowman Gray School of Medicine Winston Salem, North Carolina
1969	Undergraduate BA Magna Cum Laude in Biology Asbury College Wilmore, Kentucky

Professional Societies:

- Fellow, American College of Physicians (FACP)
- Fellow, American College of Rheumatology (FACR)
- Member, Mecklenburg County Medical Society

Professional Appointments:

1989 & 1990	Mecklenburg County Medical Society, Membership Committee
1989	Mecklenburg County Medical Society, Program Committee
1980-2002	University of North Carolina, Chapel Hill, North Carolina, Department of Medicine, Clinical Assistant Professor

Volunteer Societies:

- Charlotte Youth Ballet
 - 1990-1991 President
 - 1989-1990 President Elect
 - 1988-1989 Secretary
- Arthritis Patient Services, Community Health Services
 - 1980-1991 Founding Member, Board Member

CURRICULUM VITAE

Emily Jane Box, MD

Professional Experience:

2010-Present	Owner/MD DJL Clinical Research, PLLC Charlotte, North Carolina
2010-May 2015	Owner/MD Box Arthritis and Rheumatology of the Carolinas, PLLC Charlotte, North Carolina
2002-2010	Rheumatologist Arthritis Clinic and Carolina Bone & Joint Charlotte, North Carolina
1993-2002	Rheumatologist The Arthritis Clinic of Carolinas Physician Network Charlotte, North Carolina
1977-1993	Rheumatologist The Arthritis Clinic Charlotte, North Carolina

Publications:

Electromyography (EMG), Peripheral Nerve Conduction Velocity (PNCV), and Peripheral Vascular Studies (PVS) in Rheumatoid Arthritis.

P. Box, **J. Herron (Box)**, R. Turner, H. Green, W. Elsner, S. Bowman

Proceedings of XIV International Congress of Rheumatology (Abstract) 550

Cardiopulmonary Manifestation of Scleroderma

E. Pisko, **J. Herron (Box)**, P. Box, J. Davis, M. Parker, R. Turner

Proceedings of International Congress of Rheumatology (Abstract) 673

Piroxicam in Rheumatoid Arthritis; A Double-Blind 16 Week Study Comparing Piroxicam and Phenylbutazone

J. Herron (Box), R. Turner, P. Box, P. Wright, G. Rovere

North Carolina Medical Journal, June 1978

Piroxicam in Rheumatoid Arthritis; A Double-Blind 16 Week Study Comparing Piroxicam and Phenylbutazone

J. Herron (Box), P. Box, E. Pisko, R. Turner

Proceedings of XIV International Congress of Rheumatology, (Abstract) 966

Total Knee and Total Hip Replacement in Arthritis Therapy

J. Herron (Box), R. Turner, P. Box, P. Wright, G. Rovere

North Carolina Medical Journal, May 1979

Cardiopulmonary Manifestation of Progressive Systemic Sclerosis

E. Pisko, K. Gallup, R. Turner, M. Parker, A. Nomeir, **J. Box**, J. Davis, P. Box, H. Rothberger

Arthritis and Rheumatism, May 1979

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

Willkens RF, Urowitz MB, Stablein DM, McKendry RJ Jr, Berger RG, **Box JH**, Fiechtner JJ, Fudman EJ, Hudson NP, Marks CR, et al.

Arthritis and Rheumatism, Aug 1992

Safety Experience with Amiprilose Hydrochloride in Rheumatoid Arthritis

J. Box, P. Box, J. Clark

Eular Congress of Rheumatology, July 1993

Ulnar Bending Strength in Normal, Osteopenic, and Osteoporotic Caucasian Women

G.M. Kiebzak, **J. Box**, P. Box

Journal of Clinical Densitometry, Summer 1999

Amiprilose Hydrochloride for the Treatment of Rheumatoid Arthritis

Trentham, Daveid E.; Fife, Rose S.; Carpenter, Beverly A.; **Box, Jane Herron**; Trout, Richard; Lanser, Marc E.

Journal of Clinical Rheumatology, February 2000

Cardiopulmonary Manifestation of Progressive Systemic Sclerosis

Edward Pisko MD, Kenneth Gallup MD Assistant Professor of Medicine, Robert Turner MD Assistant Professor of Medicine, Michael Parker MD Assistant Professor of Medicine, Abdek-Moshem Nomeir Assistant Professor of Medicine, **Jane Box MD Instructor of Medicine**, John Davis MD Assistant Professor of Medicine, Pat Box MD Instructor of Medicine, Henry Rothberger MD Assistant Professor of Medicine

Arthritis and Rheumatology, December 2005

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis.

Robert F. Wilkens MD, Murray B. Urowitz MD, Donald M. Stablein Ph.D, Robert J.R. Mickendry Jr. MD, **Jane H. Box MD**, MPH Justus J. Fiechtner MD, Edward J. Fudman MD, N. Paul Hudson MD, MN Cara R. Marks RN, Raye Brooks BS, Theodore W. Rooney DO, Bernard R. Rubin DO, Frank R. Schmid MD, Allen M. Segal DO, James W. Thomas MD, Alben G. Goldstein MD, Muhammad B. Yunus MD, Robert L. Wortmann MD, Yvonne R. S. Sherrer MD

Arthritis & Rheumatology December 2005

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, **Box J**, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

New England Journal of Medicine, September 2005

Abatacept is effective at reducing pain and fatigue, and improving sleep quality in Rheumatoid Arthritis patients with an inadequate response to Anti-TNF Therapy in the attain trial.

A. Russell, Y. Sherrer, R.M. Westhovens, **J. Box**, C.H Pritchard, I. Nuamah, T.Li, M. Genovese

The European League Against Rheumatism, 2005

CURRICULUM VITAE

Emily Jane Box, MD

Efficacy and safety of Certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous diseasemodifying antirheumatic therapy: the FAST4WARD study.

R Fleischmann, J Vencovsky, R van Vollenhoven, D Borenstein, **J Box**, G Coteur, N Goel, H-P Brenzinschek, A Innes, V Strand

Annals of the Rheumatic Diseases, 2008

The ACQUIRE (Abatacept Comparison of Sub[Qu]cutaneous Verses Intravenous in Inadequate Responders to Methotrexate) Trial: A Large Phase IIIb Non-Inferiority Study.

M Genovese¹, A. Covarrubias², G. Leon³, E. Mysler⁴, M. Keiserman⁵, R. Valente⁶, P. Nash⁷, JA Simon Campos⁸, W. Porawska⁹, **J. Box**¹⁰, C. Legerton¹¹, E. Nasanovo¹², P. Durez¹³, R. Aranda¹⁴, R. Pappu¹⁴, I. Delaet¹⁴, J. Teng¹⁴ and R. Alten¹⁵

¹Stanford University, Palo Alto, CA, USA; ²Centro Medico De Las Americas, Merida, Yucatan, Mexico; ³Instituto De Ginecologia Y Reproduccion, Lima, Peru; ⁴Organizacion Medica de Investigacion, Buenos Aires, Argentina; ⁵Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil; ⁶Physician Research Collaboration, Lincoln, USA; ⁷University of Queensland, Brisbane, Australia; ⁸Centro De Especialidades Medicas, Merida, Mexico; ⁹Pozanski Osrodek Medyczny 'Novamed', Ponzan, Poland; ¹⁰The Arthritis Clinic & Carolina Bone & Joint, Charlotte, USA; ¹¹Department of Medicine, Medical University of South Carolina, Charleston, USA; ¹²Institute of Rheumatology, Moscow, Russia; ¹³Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; ¹⁴Bristol-Myers Squibb Co., Princeton, NJ, USA; ¹⁵Schlosspark-Klinik, Charite, Univ Medicine Berlin, Berlin, Department of Internal Medicine II, Rheumatology.

Arthritis and Rheumatism. May 2011.

Subcutaneous Abatacept vs Intravenous Abatacept: Results From A Phase IIIb Non-Inferiority Study in Patients with an Inadequate Response to MTX.

Genovese MC¹, Covarrubias A², Leon G³, Mysler E⁴, Keiserman M⁵, Valente R⁶, Nash P⁷, Simon Campos JA⁸, Porawska W⁹, **Box J**¹⁰, Legerton C¹¹, Nasanovo E¹², Durez P¹³, Aranda R¹⁴, Pappu R¹⁴, Delaet I¹⁴, Teng J¹⁴, Alten R¹⁵

¹Stanford University, Palo Alto, CA, USA; ²Centro Medico De Las Americas, Merida, Yucatan, Mexico; ³Instituto De Ginecologia Y Reproduccion, Lima, Peru; ⁴Organizacion Medica de Investigacion, Buenos Aires, Argentina; ⁵Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil; ⁶Physician Research Collaboration, Lincoln, USA; ⁷University of Queensland, Brisbane, Australia; ⁸Centro De Especialidades Medicas, Merida, Mexico; ⁹Pozanski Osrodek Medyczny 'Novamed', Ponzan, Poland; ¹⁰The Arthritis Clinic & Carolina Bone & Joint, Charlotte, USA; ¹¹Department of Medicine, Medical University of South Carolina, Charleston, USA; ¹²Institute of Rheumatology, Moscow, Russia; ¹³Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; ¹⁴Bristol-Myers Squibb Co., Princeton, NJ, USA; ¹⁵Schlosspark-Klinik, Charite, Univ Medicine Berlin, Berlin, Department of Internal Medicine II, Rheumatology.

Arthritis and Rheumatism. May 2011.

Results of a Randomized, Placebo-Controlled, Phase 2a Study of Sifalimumab, an Anti-Interferon- α Monoclonal Antibody, Administered Subcutaneously in Subject with Systemic Lupus Erythematosus
J. Merrill¹, V. Chindalore², **J. Box**³, N. Rothfield⁴, J. Fiechtner⁵, D. Paul⁶, J. Sun⁷, D. Ethgen⁷

¹Oklahoma Medical Research Foundation, Oklahoma City, OK; ²Pinnacle Research Group, Anniston, AL; ³Carolina Bone and Joint, Charlotte, NC; ⁴University of Connecticut Health Center, Farmington, CT; ⁵Justus J. Fiechtner, MD, Lansing, MI; ⁶Rheumatology Arthritis Center, Peachtree City, GA; ⁷MedImmune, LLC, Gaithersburg.

Annals of the Rheumatic Diseases 2011

Results of Randomized, Placebo-Controlled, Phase 2a Study of Sifalimumab, an Anti-Interferon- α Monoclonal Antibody, Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus. Joan Merrill, MD¹, Vishala Chindalore, MD², **Jane Box, MD³**, Naomi Rothfield, MD⁴, Justus Fiechtner, MD, MPH⁵, Jichao Sun, PhD⁶, and Dominique Ethgen, MD⁶

¹Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; ²Pinnacle Research Group, LLC, Anniston, Alabama, USA; ³Box Arthritis and Rheumatology of the Carolinas, PLLC, Charlotte, NC, USA; ⁴University of Connecticut Health Center, Farmington, CT, USA; ⁵Michigan State University, Lansing, MI, USA; ⁶MedImmune, LLC, Gaithersburg, MD, USA.

Annual European League Against Rheumatism Congress, May 25-28, 2011, London, United Kingdom.

Switching Patients with Rheumatoid Arthritis from Intravenous to Subcutaneous Abatacept is Well Tolerated and Sustains Previously Established Efficacy.

E Keystone¹, J Kremer², A Russell³, **J Box⁴**, C Abud Mendoza⁵, MA Garza-Elizondo⁶, A Luo⁷, R Aranda⁷, I Delaet⁷, R Swanink⁸, S Gujrathi⁷, M Luggen⁹

¹University of Toronto and Mount Sinai Hospital. Toronto, ON, Canada; ²Albany Medical College, Albany, NY, United States; ³University of Alberta, Edmonton, AB, Canada; ⁴Box Arthritis and Rheumatology of the Carolinas, Charlotte, NC, United States; ⁵Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosi, SLP, Mexico; ⁶Faculty of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico; ⁷Bristol-Myers Squibb, Princeton, NJ, United States; ⁸Bristol-Myers Squibb, Braine-l'Alleud, Belgium; ⁹Division of Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.

EULAR Annual Congress. May 25-28, 2011. London, UK.

Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to Methotrexate) Trail

Mark C. Genovese¹, Arturo Covarrubias Cobos², Gustavo Leon³, Eduardo F. Mysler⁴, Mauro W. Keiserman⁵, Robert M. Valente⁶, Pete T. Nash⁷, J. Abraham Simon Campos⁸, Wieslawa Porawska⁹, **Jane H. Box¹⁰**, Clarence W. Legerton III¹¹, Evgeny L. Nasonov¹², Patrick Durez¹³, Ramesh Pappu¹⁴, Ingrid Delaet¹⁴, Julie Teng¹⁴ and Rieke Alten¹⁵, ¹Stanford Univ Medical Center, Palo Alto, CA, ²Callie Maiz No 49, Mexico, Mexico, ³Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁴OMI, Buenos Aires, Argentina, ⁵Pontifical Catholic Univ, Porto Alegre, Brazil, ⁶Arthritis Center of Nebraska, Lincoln, NE, ⁷University of Queensland, Brisbane, Australia, ⁸Centro De Especialidades Medicas, Merida, Mexico, ⁹Pozanski Ocerodek Medyczny 'Novamed', Poznan, Poland, ¹⁰Box Arthritis & Rheumatology of the Carolinas, Charlotte, NC, ¹¹LowCountry Rheumatology, Charleston, SC, ¹²Institute of Rheumatology, Moscow, ¹³Universite Catholique de Louvain, Brussels, Belgium, ¹⁴Bristol-Myers Squibb, Princeton, NJ, ¹⁵Schlosspark-Klinik, Berlin, Germany

ACR June 2011

Abatacept in Subjects who Switch from Intravenous to Subcutaneous Therapy: Results from the Phase IIIB ATTUNE Study

E Keystone¹, JM Krmer², AS Russell³, **J Box⁴**, C Abud Mendoza⁵, MA Garza-Elizondo⁶, A Luo⁷, R Aranda⁷, I Delaet⁷, R Swanink⁸, S Gujrathi⁷, M Luggen⁹, ¹University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada; ²Albany Medical College, Albany, NY, USA; ³University of Alberta, Edmonton, AB, Canada; ⁴Box Arthritis and Rheumatology of the Carolinas, Charlotte, NC, USA; ⁵Regional Unit of Rheumatology, Faculty of Medicine and Central Hospital, University of San Luis Potosi, SLP, Mexico; ⁶Faulty of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico; ⁷Bristol-

CURRICULUM VITAE

Emily Jane Box, MD

Myers Squibb, Princeton, NJ, USA; 8Bristol-Myers Squibb, Braine-l'Alleud, Belgium; 9Division of Immunology, University of Cincinnati College of Medicine, Cincinnati, OH, USA
Annals of the Rheumatic Diseases October 2011

Subcutaneous Abatacept vs Intravenous Abatacept: Results from a Phase IIIb Non-Inferiority Study in Patients with an Inadequate Response to MTX

1Stanford University, Palo Alto, CA, US; 2Centro Medico De Las Americas, Merida, Yucatan, Mexico; 3Instituto De Ginecologia Y Reproduccion, Lima, Peru; 4Organizacion Medica de Investigacion, Buenos Aires, Argentina; 5Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil; 6Physician Research Collaboration, Lincoln, US; 7University of Queensland, Brisbane, Australia; 8Centro De Especialidades Medicas, Merida, Mexico; 9Poznanski Osrodek Medyczny 'Novamed', Ponzan, Poland; **10Box Arthritis & Rheumatology of the Carolinas**, Charlotte, US; 11Department of Medicine, Medical University of South Carolina, Charleston, US; 12Institute of Rheumatology, Moscow, Russia; 13Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; 14Bristol-Myers Squibb Co., Princeton, NJ, US; 15Schlosspark-Klinik, Charite, University Medicine Berlin, Department of Internal Medicine II, Rheumatology
Arthritis and Rheumatism 2011

Subcutaneous versus Intravenous Abatacept in RA: Post-Hoc Efficacy Analysis of Long-term acquire (SC) Data with AIM (IV) Data

1Patrick Durez; 2J Abraham Simon Campos; 3Eduardo Mysler; 4Ingrid Delaet; 5Robert Valente; 6JA Covarrubias Cobos; 7Ayanbloa Elegbe; 8Cesar Pacheco-Tena; 9Peter Nash; 10Gustavo Leon; 11Rieke Alten; 12Eugeni Nasonov; **13Jane Box**; 14Chip Legerton
Eular Poster June 2012

Subcutaneous Abatacept Long-term Data from the ACQUIRE Trial-as a poster presentation for ACR 2012
Patrick Durez, Eugeni Nasonov, Gustavo Leon, J Abraham Simon Campos, Peter Nash, Robert Valente, Mauro Keiserman, Cesar Pacheco-Tena, JA Covarrubias Cobos, Jane Box, Eduardo Mysler, Chip Legerton, Ingrid Delaet

Rheumatoid Arthritis: Advances in Treatment "Hands need to close, feet need to be walked on and knees need to help climb stairs"

Jane Box

Arthritis Services Outreach 2013

Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial.

Mark C Genovese, Cesar Pacheco Tena, Srturo Covarrubias, Gustavo Leon, Eduardo Mysler, Mauro Keiserman, Robert Valente, Peter Nash, J Abraham Simon-Campos, **Jane Box**, Clarence William Legerton, Evgeny Nasonov, Patrick Durez, Ingrid Celaet, Julie Teng, Rieke Alten
The Journal of Rheumatology March 2014

Five-Year Efficacy and Safety of Subcutaneous Abatacept In Patients with Moderate to Severely Active RA and an Inadequate Response to MTX: Long-Term Extension of the Phase III, Double-Blind, Randomized ACQUIRE Study

MC Genovese, C Pacheco Tena, A Covarrubias, G Leon, E Mysler, M Keiserman, R Valente, P Nash, JA Simon-Campos, **J Box**, CW Legerton III, E Nasonov, P Durez, A Elegbe, R Wong, X Li, S Banerjee, R Alten (Abstract) The European League Against Rheumatism. January 2016

Five-Year Efficacy and Safety of Subcutaneous Abatacept In Patients with Moderate to Severely Active RA and an Inadequate Response to MTX: Long-Term Extension of the Phase III, Double-Blind, Randomized ACQUIRE Study

MC Genovese, C Pacheco Tena, A Covarrubias, G Leon, E Mysler, M Keiserman, R Valente, P Nash, JA Simon-Campos, **J Box**, CW Legerton III, E Nasonov, P Durez, A Elegbe, R Wong, X Li, S Banerjee, R Alten (Abstract) The Journal of Rheumatology. April 2018.

A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis

Cynthia Aranow, John Cush, Marcy B Bolster, Christopher C Striebich, Maria Dall'era, Meggan Mackay, Ewa Olech, Tracy Frech, **Jane Box**, Richard Keating, Mary Chester Wasko, William St Clair, Alan Kivitz, Weiquang Huang, PetaGay Ricketts, Beverly Welch, Sherrie Callahan, Meagan Spsychala, Karen Boyle, Kate York, Lynette Keyes-Elstein, Ellen Goldmuntz, Betty Diamond, Anne Davidson
Rheumatology, kez471, Published: 18 October 2019

Training:

Has received skin and joint assessment training from multiple sponsors over the 40 years of conducting clinical research trials by BMS, Cephalon, Teva, Abbott, etc.

Clinical Research:

- Ayerst Laboratories
 1. Ultradol in treatment of RA
 - Double-blind long term study
 2. Ultradol in treatment of OA of knees
 - Double-blind study
 - Open label long term study
- Beecham Laboratories
 1. Nabumetone vs Naproxen in RA
 - Double-blind study
 - Nabumetone open label long term study
 2. Nabumetone vs Naproxen in OA of knees
 - Double-blind study
 - Nabumetone open label long term study
- Burroughs Wellcome
 1. Combination of Imuran and Methotrexate vs Methotrexate and Placebo vs Imuran and Placebo
 - Double-blind study
- Ciba Geigy Laboratories
 1. Voltaren in treatment of RA
 2. Voltaren in treatment of OA
 - Open label study
 3. Open label study of marketed NSAID in treatment of OA
 4. Open label study of marketed NSAID in treatment of RA
 5. Open label study of Voltaren in treatment of RA

CURRICULUM VITAE

Emily Jane Box, MD

6. Pironimide in RA
- Greenwich Pharmaceuticals
 1. Therafectin RA9 vs Placebo in treatment of RA
 - Double-blind study
 2. Therafectin RA9E in treatment of RA
 - Open label long term study
 3. Therafectin RA10 vs Placebo in treatment of RA
 - Double-blind study
 4. Therafectin RA10E
 - Open label long term
 5. Therafectin RA11 vs Placebo in treatment of RA
 - Double-blind study
 6. Therafectin RA11E in treatment of RA
 - Open label long term study
 7. Therafectin RA12 in treatment of RA with extension
- Hoechst-Roussel Laboratories
 1. Artil vs Indomethacin in treatment of RA
 2. Artil vs Placebo in treatment of RA
- McNeil Laboratories
 1. Tolectin in treatment of RA
- Merck Sharp and Dohme
 1. Indocin Gits in treatment of RA
 2. Indos 4/50 in treatment of OA of the knees
 3. Diflunisal RAF vs Diflunisal in treatment of OA
- Pfizer
 1. Tenidap in treatment of RA
 - Double-blind study with extension - Tenidap vs Naproxen
 2. Tenidap in treatment of OA
 - Double-blind study with extension - Tenidap vs Naproxen
- Proctor and Gamble
 1. A multi-center, randomized, double-blind, placebo controlled, parallel group study to determine the safety and efficacy of Risedronate in the treatment of osteoporosis in elderly women
- Purdue Frederick
 1. Indomethacin CR 75 mg in treatment of RA
 - Double-blind parallel group – Indomethacin CR vs Indocin SR
 2. Indomethacin CR in treatment of RA
 - Open label study extension
- A.H. Robins
 1. Bromfenac vs Aspirin in treatment of OA of the knees

- Open label study extension
- Searle
 1. A comparison of the efficacy of a fixed combination of Diclofenac/Misoprostol vs Diclofenac/Placebo in treating the signs and symptoms of Ankylosing Spondylitis
 2. A study of the effect of Misoprostol 50 mcg, 100 mcg, 200 mcg vs placebo on the antiarthritic efficacy of and upper GI injury induced by Diclofenac 50 mcg TID in patients with RA or OA
 3. A multi-center, double-blind, placebo controlled, randomized comparison study of the efficacy and upper gastrointestinal safety of 50 mg, 100 mg, and 200 mg SC-58635 BID in treating the signs and symptoms of osteoarthritis
 4. Clinical protocol to evaluate the long term safety of SC-58635 in treating the signs and symptoms of osteoarthritis and rheumatoid arthritis
 5. Clinical protocol for a multi-center, double-blind, parallel group study comparing the incidence of clinically significant upper gastrointestinal adverse events associated with SC-58635 400 mg BID to that of Diclofenac 75 mg BID in patients with OA or RA
- Upjohn Laboratories
 1. Flurbiprofen vs ASA in RA
 2. Flurbiprofen in treatment of OA
 3. Flurbiprofen BID vs QID in RA
 4. Arbacet treatment of ASA or NSAID induced gastric mucosal damage
 5. Motrin SR 800 mg vs Motrin 600 mg
- Wyeth Ayerst
 1. Double-blind, parallel, placebo controlled comparison of the safety and efficacy of Bromfenac and Naproxen in patients with active osteoarthritis of the hip and/or knee with a long term open label extension
 2. A four week double-blind, placebo controlled comparison of the safety and efficacy of orally administered Lodine and Naproxen in patients with active osteoarthritis of the knee
 3. Placebo controlled comparison of the efficacy and safety of Etodolac Extended Release with Nabumetone in patients with active rheumatoid arthritis followed by a long term open label extension
 4. Double-blind placebo controlled comparison of the efficacy and safety of two doses of Etodolac Extended Release with Nabumetone followed by an open label extension with Etodolac Extended Release for up to two years in patients with osteoarthritis of the knee
 5. A randomized, double-blind comparison of the efficacy and safety of Hylan G-F and saline in patients with osteoarthritis of the knee
- Snow Brand Milk Products Co., Ltd
 1. A double-blind, randomized, placebo controlled study of SNI-2011 (15 mg and 30 mg TID) vs placebo in Sjogren's Syndrome patients with Xerostomia and Keratoconjunctivitis SICCA

CURRICULUM VITAE
Emily Jane Box, MD

2. An open label chronic safety study of SNI-2011 (15 mg, 30 mg, and 60 mg TID) in Sjogren's Syndrome patients with Xerostomia and Keratoconjunctivitis SICCA
- Boston Life Sciences, Inc.
 1. A double-blind randomized study of Therafectin (Amiprolase HCl) 6 grams/day compared to placebo in patients with rheumatoid arthritis withdrawn range of motion their non-steroidal anti-inflammatory drug therapy
 2. An open label extension of Therafectin (Amiprolase HCl) 6 grams/day in patients completing protocol RAB-1
 - AutoImmune
 1. An open label, long term safety study of chronically administered Oral Colloral (chicken type II Collagen - BBIND 6412) in adult patients with rheumatoid who have participated in Colloral Study AI-200-007, AI-200-008, or AI-200-009
 2. A phase II double-blind, randomized, four group, parallel, placebo controlled dose refinement study of Colloral in adult patients with rheumatoid arthritis
 - Millennium Pharmaceuticals, Inc.
 1. Rheumatoid arthritis genetic epidemiology study
 - Purdue Pharma L.P.
 1. A randomized, placebo controlled, double-blind, parallel group safety and efficacy assessment of OxyContin and Immediate Release Oxycodone/APAP in patients with chronic non-malignant pain due to osteoarthritis
 - Merck and Co., Inc.
 1. An active comparator and placebo controlled, parallel group, six week, double-blind study conducted under in house building to assess the efficacy, safety, and tolerability of MK-0966 in patients aged eighty and over with osteoarthritis of the knee or hip
 2. A placebo, parallel-group, double-blind study to assess safety and to define the clinically effective dose range of L-791, 456 in patients with osteoarthritis of the knee, followed by a double-blind, active comparator controlled extension
 3. An active-comparator and placebo controlled, parallel-group, double-blind, 52 week study to assess the safety and efficacy of MC-0966 in rheumatoid arthritis patients
 4. A 1 year randomized, placebo and active-comparator-controlled, parallel-group, double-blind, 2-part study to assess the safety and efficacy of MK-0966 vs Naproxen in patients with osteoarthritis
 5. A placebo-controlled, parallel group, 4-week trial conducted under double-blind conditions to assess the efficacy and safety to Rofecoxib in patients with chronic low back pain
 - Amgen
 1. A twenty four week study to evaluate the safety and efficacy of Anakinra therapy in the presence of background Methotrexate in patients with active rheumatoid arthritis
 2. An open-label extension study to evaluate the long term safety of Anakinra therapy in the presence of background Methotrexate in patients with rheumatoid arthritis

3. A multi-center, blinded, randomized, placebo controlled trial to study the ability of IL-1ra (Anakinra) to retard joint destruction and evaluate the long term safety of IL-1ra in subjects with rheumatoid arthritis
 4. A multi-center double-blind study to evaluate the safety and efficacy of Anakinra (r-methHUIL-1ra) and Etanercept in subjects with rheumatoid arthritis using Methotrexate
 5. A multi-center, open-label extension study to evaluate the safety of Anakinra (r-methHUIL-1ra) alone or in combination with Etanercept in subjects completing Study 20000223
- TAP Holdings, Inc.
 1. A multiple dose response study of oral TAK-603/A-165646 in rheumatoid arthritis patients
 - Anika Therapeutics
 1. A dose-ranging and arthrocentesis-controlled study of the safety and efficacy of Intra-articular ORTHOVISC® sodium Hyaluronate injections in providing symptomatic relief of osteoarthritis of the knee
 - Napp Pharmaceuticals
 1. An open-label run-in, followed by a randomized, double-blind placebo controlled, parallel group study to show the effectiveness of Buprenorphine Transdermal Delivery System (BTDS) -5, 10, and 20 mg therapy in the management of patients with chronic non-malignant pain syndromes responsive to Opioid combination therapy
 - Endo Pharmaceuticals
 1. A double-blind, placebo controlled, parallel group, dose ranging comparison of the efficacy and safety of extended release oxymorphone and placebo in the treatment of osteoarthritis of the knee and/or hip
 - Almirall Prodesfarma, S.A.
 1. A phase II, randomized, double-blind, placebo controlled, parallel group, multi-center, clinical trial to evaluate the safety and efficacy of three doses of LAS 34475 vs placebo and Naproxen 500 mg in patients with Osteoarthritis of the knee

Principal Investigator-Alexion Pharmaceuticals CO1-004: A Phase IIIb Randomized, Double-Blind, Placebo-Controlled Study of the Effect of h5g1.1-mAb on Rheumatoid Arthritis Patients with Active Disease Despite Receiving Methotrexate or Leflunomide.

Principal Investigator-Alexion Pharmaceuticals E01-004: Extension Study of h5g1.1-mAb in Rheumatoid Arthritis Patients Receiving Methotrexate or Leflunomide who Participated in C01-004.

Sub-Investigator-Genentech BRT3321g: A phase 1, randomized, placebo controlled, double blind, multi-center study of the safety, tolerability, pharmacokinetics, in pharmacodynamics of single escalating doses of PRO97796 in adults with rheumatoid arthritis.

Sub-Investigator-Ortho Biotech PR03-33-055: A randomized, double blind, placebo controlled study to assess the fatigue in patient with anemia of chronic disease due to rheumatoid arthritis receiving procrit.

CURRICULUM VITAE

Emily Jane Box, MD

Principal Investigator-Wyeth 3066A3-206-WW: A Double-Blind, Parallel, Placebo- Controlled, Randomized Study to Evaluate the Efficacy and Safety of Three Different Oral Dose Levels (1, 2, and 4mg) of CCI-779 in Subjects with Active Rheumatoid Arthritis on Concomitant Methotrexate. (2004)

Principal Investigator-Bristol Myers Squibb IM101-043: A Phase III, Multi-center, randomized, double blind, placebo controlled comparative study of abatacept or infliximab in combination with methotrexate in controlling disease activity in subjects with rheumatoid arthritis having an inadequate clinical response to methotrexate. (2004)

Principal Investigator -TAP Pharmaceuticals C02-009: A phase III Randomized Multicenter Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subject with Gout. (2005)

Principal Investigator-TAP Pharmaceuticals C02-021: Open Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects with Gout. (2005)

Principal Investigator-Merck MK-0663: A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients with Osteoarthritis or Rheumatoid Arthritis. (2005)

Principal Investigator-Fibromyalgia Clinical Criteria Study, Fibromyalgia Diagnostic Criteria Organizing Group (FMCOG), National Databank for Rheumatic Diseases (2005)

Principal Investigator-Celltech 027: A Phase III multicenter, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilized CDP870 given subcutaneously as additional medication to methotrexate in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate. (2005)

Sub-Investigator-Roche 17823: A randomized, double-blind, parallel group study of the safety and efficacy of MRA versus placebo, in combination with methotrexate, in preventing structural joint damage in patients with moderate to severe active Rheumatoid Arthritis. (2005)

Principal Investigator-Bristol-Myers Squibb IM101-029: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 vs. Placebo in Subjects with Active Rheumatoid Arthritis on Background DMARDS who have failed an Anti-TNF Therapy. (2005)

Principal Investigator-Pfizer A3921019: A 12-week, phase 2 randomized, double-blind, placebo-controlled, multicenter study to compare 3 dose levels of oral CP-690, 550 versus placebo in the treatment of the signs and symptoms of patients with active rheumatoid arthritis. (2005)

Principal Investigator-Abbott M04-684: Randomized, double-blind (first dose), placebo-controlled, multicenter, Phase IV study of adalimumab in the United States, designed to demonstrate the early efficacy, safety, and tolerability of adalimumab in the treatment of subjects with active RA. (2005)

Principal Investigator-Novartis COX189A2369: A 52-week, international, multicenter randomized, double blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg dose, lumiracoxib 100mg bid and celecoxib 200mg dose in patients with primary osteoarthritis of hip, knee, hand or spine. (2005)

Sub-Investigator-Merrimack Pharmaceuticals MM-093-01-200: A phase 2, double blind, parallel, placebo controlled, randomized study to evaluate the efficacy and safety of 3 different dose levels (2.5, 7.5 and 20 mg) of MM-093 in patients with active rheumatoid arthritis with stable doses of methotrexate. (2005)

Sub-Investigator-Glaxo Smith Kline CXA30009: Phase III, 12-Week, Multicentre, Double-Blind, Randomized, Placebo-and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg and 50mg administered orally once daily, in Adults with Rheumatoid Arthritis. (2005)

Principal Investigator-Teva TV-4710/201: (Prelude) A multi-center, randomized, double-blind, placebo-controlled, multiple dose, parallel group study to assess the efficacy, tolerability and safety of three doses of Edratide (TV-4710) Administered Subcutaneously to Systemic Lupus Erythematosus (SLE) Patients. (2005)

Principal Investigator-Protocol A3921024: A long-term, open-label, follow-up study of CP-690,550, A moderately selective Janus-Kinase-3 inhibitor, for treatment of rheumatoid arthritis (2005) ***High enrolling site**

Principal Investigator-Wyeth: A randomized, parallel, double-blind, placebo-controlled study to evaluate the efficacy and safety of 3 oral doses of ERB-041 in subjects with rheumatoid arthritis on a background of Methotrexate Therapy. (2005)

Principal Investigator-Roche WA18062: A randomized, double-blind, placebo controlled parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis and an inadequate response to previous anti TNF therapy. (2005)

Sub-Investigator-Bristol Myer Squibb: A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs who have an inadequate response to Anti-TNF Therapy and Have Limited Therapeutic Options. (2005)

Principal Investigator- Protocol M03-666: An open-label study evaluating the safety and tolerability of long term administration of hydrocodone/acetaminophen extended release tablets (Vicodin CR) in subjects with moderate to severe chronic non-malignant pain (2005)

Principal Investigator-C0524T12: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Intravenous Golimumab, a Fully Human Anti-TNF α Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy (2006)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator-Abbott M03-643: A randomized, multi-center, double-blind study comparing the analgesic efficacy of extended release hydrocodone/acetaminophen (Vicodin CR) and placebo in subjects with osteoarthritis. (2006)

Principal Investigator-Purdue Pharma BUP3019: Randomized, Double-blind, Multicenter, Active Comparator Study to determine the efficacy and safety of BTDS 20 or OxyIR versus BTDS 5 in subjects with moderate to severe osteoarthritis (OA) pain. (2006)

Principal Investigator-Protocol #WA20494/ACT3985g: A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis continuing Methotrexate Treatment (2006)

Principal Investigator-NIH Protocol ARA02: A double blind, placebo controlled, phase II, randomized study of Lovastatin therapy in the treatment of mildly active rheumatoid arthritis (2006)

Principal Investigator-Protocol A3921025: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Compare 6 Dose Regimens of CP-690,550 vs. Placebo, each Combined with Methotrexate, Administered for 6 Months in the Treatment of Subjects with Active Rheumatoid Arthritis Who have had an Inadequate Response to Methotrexate Alone (2006)

Principal Investigator-Protocol A3921029: A prospective observational study to evaluate long-term safety and functional status of subjects with rheumatoid arthritis previously enrolled in studies of CP-690,550 (2006)

Principal Investigator-Protocol CHTF919N2201: A randomized, double-blind, placebo-controlled multicenter phase II/III study to evaluate the efficacy and safety of Tegaserod and placebo given orally for 12 weeks for the treatment of opioid-induced constipation (OIC) in patients with chronic non-cancer pain (2006)

Sub-Investigator-Protocol ALO-KNT-301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee (2006)

Sub-Investigator-Protocol ALO-KNT-302: A Long-Term, Open-Label, Safety of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Chronic Moderate to Severe Nonmalignant Pain (2006)

Sub-Investigator-Protocol RN-624 CL006: A Randomized, Parallel Arm, Placebo-Controlled, Double-Blind, Multi-Dose Study of the Safety and Efficacy of RN624 in Adults with Moderate-to-Severe Pain Due to Osteoarthritis of the Knee (2006)

Sub-Investigator-Jazz Pharmaceuticals Protocol 06-008: A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia (2006)

Sub-Investigator- Pfizer Protocol A3191331: Gastrointestinal (GI) Randomized Event and Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blind-Endpoint, Parallel-Group Trial of GI Safety of Celecoxib Compared with Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDs) in Osteoarthritis Patients (2006)

Principal Investigator- Genentech Protocol U3839g: A long-term study of the safety of Rituxan in patients with rheumatoid arthritis after an inadequate response to previous anti-TNF therapy (Sunstone) (2006)

Principal Investigator- Purdue BUP-3018: A Randomized, Double-Blind Study to Evaluate the Dose Conversion from Vicodin to Buprenorphine Transdermal System (BTDS) in Subjects with Osteoarthritis Pain. (2006)

Principal Investigator- BMS Protocol IM101023: A Phase IIIB Multi-Center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naïve Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with Methotrexate (2006)

Sub-Investigator- Human Genome Sciences LBS99: A multi-center, open-label, continuation trial of Lymphostat-B Antibody (Monoclonal Anti-BlyS antibody) in subjects with Systemic Lupus Erythematosus (SLE) who completed the phase 2 protocol LBSL02 (2007)

Sub-Investigator- Human Genome Sciences LBSL02: A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphostatB Antibody (Monoclonal Anti-BlyS Antibody) in Patients with Systemic Lupus Erythematosus (SLE). (2007)

Sub-Investigator- Jazz Pharmaceuticals Protocol 06-010: A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia (2007)

Sub-Investigator- Abbott Protocol M06-810: A Multicenter, Randomized, Double-period, Double-Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis (OPTIMA) (2007)

Sub-Investigator- Human Genome Sciences LBRA01: A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphostatB Antibody (Monoclonal Anti-BlyS Antibody) in Patients with Rheumatoid Arthritis (RA). (2007)

Principal Investigator- Novartis COX189A2360: A 13-week Multicenter Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Trial of Two Different Dose Regimens of (Lumiracoxib 100mg dose and 200mg dose Initial Dose for Two Weeks Followed by 100mg od) in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200mg od) as a Comparator. (2007)

Principal Investigator- Pharmacia Protocol 870-IFL-0587-011: Efficacy and Safety of CDP-870 400mg Subcutaneous versus Placebo in the Treatment of the Signs and Symptoms of Patients with Rheumatoid Arthritis who have Previously Failed at Least One DMARD. (2007)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator-Pharmacia Protocol 870-IFL-0587-015: A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP-870 400mg Subcutaneous Every Four Weeks in Patients with Rheumatoid Arthritis. (2007)

Principal Investigator-Genentech Protocol WA20497/ACT3984g: A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocerlizumab in Combination with Methotrexate (MTX) compared to MTX alone in Methotrexate-Naïve Patients with Active Rheumatoid Arthritis (2007)

Principal Investigator-Protocol WA20495/ACT3986g: A Randomized, Double-Blind, Parallel group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients with Active Rheumatoid Arthritis who have an Inadequate Response to at Least one anti-TNF- α therapy (2007)

Principal Investigator-BMS Protocol IM101158: A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis (2007)

Principal Investigator-Roche ML21136 Protocol: A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of tocilizumab versus placebo in combination with disease modifying anti-rheumatic drugs in patients with moderate to severe active rheumatoid arthritis (2007)

Principal Investigator- Bristol Myer Squibb IM101023: A phase IIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naïve, Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with Methotrexate. (2007)

Sub-Investigator-Protocol U3924g: An Open-Label, Prospective Study of the Safety of Rituximab in Combination with Other Disease-Modifying Anti-Rheumatic Drugs in Subjects with Active Rheumatoid Arthritis (2007)

Principal Investigator-MedImmune Protocol MI-CP151: A Phase 1B, randomized, double-blind, placebo-controlled, multicenter study to evaluate safety of multiple-dose, intravenously administered MEDI-545, a fully human anti-interferon-alpha monoclonal antibody, in adult patients with dermatomyositis or polymyositis (2007)

Principal Investigator-Protocol # WA20499/ACT4071g: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (2007)

Principal Investigator-Celltech CDP870-028: A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilized CDP870 and engineered human anti-TNF PEG conjugate, dosed subcutaneously at 400 mg every two weeks as additional medication to methotrexate, in the treatment of signs and symptoms and preventing structural damage in patients with active rheumatoid arthritis. (2008)

Principal Investigator-Protocol #WA20500/ACT4071g: A Randomised, Double-Blind, Placebo Controlled, Multicenter, Parallel-Group study designed to Evaluate the Efficacy and Safety of Ocrelizumab added to SOC(corticosteroid plus one of two immunosuppressant regimens) compared with placebo added to SOC in patients with ISN/RPS or WHO class III or IV lupus nephritis (2008)

Principal Investigator-Wyeth-Protocol 3206K1-2203-WW: A randomized, parallel, double-blind, placebo-controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in subjects with active seropositive rheumatoid arthritis on a stable background of methotrexate (2008)

Principal Investigator-J&J/Centacor Protocol C1377T04: A phase 2,2-part, multicenter, randomized, double-blind, parallel-group, placebo-controlled, proof-of-concept, dose-finding study evaluating the efficacy and safety of CNTO 136 administered subcutaneously in subjects with active rheumatoid arthritis despite methotrexate therapy (2008)

Sub-Investigator-Pharmanet/Pfizer Protocol A4091014: A phase 3 randomized, double-blind, placebo-controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip (2008)

Sub-Investigator-UCB Protocol C87094: A phase IIIb, multicenter study with a 12 week double-blind, placebo controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis (2008)

Sub-Investigator-Neuromed Protocol NMT 1077-302: A phase III, flexible-dose titration followed by a randomized double-blind study of controlled-release OROS Hydromorphone HCl (NMED-1077) compared to placebo in patients with osteoarthritis pain (2008)

Principal Investigator-Pfizer Protocol A3921045: Phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of CP-690,550 monotherapy in patients with active rheumatoid arthritis (2008)

Principal Investigator-Wyeth Protocol TRU-015: A randomized, parallel, double-blind, placebo-controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in subjects with active seropositive rheumatoid arthritis on a stable background of methotrexate (2008)

Principal Investigator-NIH Protocol ARA05: Switching anti-TNF- α agents in patients with RA with an inadequate response to TNF- α inhibition (2008)

Principal Investigator-Genentech Protocol ACT4562g: A phase II, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in combination with Methotrexate compared with Infliximab plus Methotrexate in patients with active rheumatoid arthritis currently responding inadequately to Etanercept or Adalimumab (2008)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator-Genentech IFN4575g: A phase II, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Rontalizumab (rhuMab IFNalpha) in patients with moderately to severely active Systemic Lupus Erythematosus (2008)

Principal Investigator-Bristol Myers Squibb-Protocol IM101185: A phase 3B multi-center open-label study to evaluate the safety of abatacept in subjects who switch from intravenous to subcutaneous abatacept therapy (2008)

Principal Investigator-MedImmune Protocol MI-CP179: A phase 2A, multicenter, randomized, double-blind, placebo-controlled, parallel-dose study to evaluate the safety and tolerability of multiple subcutaneous doses of MEDI-545, a fully human anti-interferon-alpha monoclonal antibody, in subjects with systemic lupus erythematosus (2008)

Principal Investigator-UCB Protocol C87077: A phase IIIb open-label run-in and double-blind randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis (2008)

Sub-Investigator-Pfizer Protocol A4091016: A Phase 2, Multicenter, Randomized, Long Term Study of the Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hip (2008)

Principal Investigator-BMS Protocol 174: A phase IIB multicenter, randomized, double-blind, double-dummy study to compare the efficacy and safety of abatacept administered subcutaneously and intravenously in subjects with rheumatoid arthritis, receiving background methotrexate, and experiencing an inadequate response to methotrexate (2008)

Principal Investigator-Protocol SL0007: A Phase IIB Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease (2009)

Sub-Investigator-Human Genome Sciences LBRA99: A multi-center, open-label, continuation trial of Lymphostat-B Antibody (Monoclonal Anti-BlyS antibody) in subjects with Rheumatoid Arthritis who completed the phase 2 protocol LBRA01. (2009)

Sub-Investigator-Pfizer Protocol A4091015: A Phase 3 Randomized, Double Blind Placebo and Naproxen Controlled Multicenter Study of the Analgesic Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee (2009)

Principal Investigator-Endo Pharmaceuticals EN3220-013: A Randomized, Open-label study comparing the efficacy and safety of Lidocaine 5% Patch with Celecoxib 200mg in patients with chronic axial low back pain. (2009)

Principal Investigator-Regeneron Protocol 6R88-0802: A multi-center, randomized, double-blind, placebo-controlled, ascending parallel group study of the safety and tolerability of REGN88 in subjects with Rheumatoid Arthritis receiving concomitant Methotrexate (2009)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator-Pfizer Protocol A3921046: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 2 Doses of CP-690,550 in Patients with Active Rheumatoid Arthritis on Background DMARDS (2009)

Principal Investigator-Luitpold Pharmaceuticals Protocol 1VIT09031: A Multi-Center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients with Iron Deficiency Anemia (IDA) (2009)

Principal Investigator-Roche Protocol ML22533: An Open-Label, Randomized Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab (TCZ) Monotherapy or TCZ in Combination with Non-Biologic or Biologic DMARDs (2009)

Principal Investigator-Protocol SL0008: A Phase IIb, Multi-center, Open-Label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007 (2010) ***High enrolling site**

Principal Investigator-Luitpold Pharmaceuticals Protocol 1VIT08019: A multi-center, randomized, controlled study to investigate the safety and tolerability of intravenous ferric carboxymaltose (FCM) vs. standard medical care in treating iron deficiency anemia (2010)

Principal Investigator-Luitpold Pharmaceuticals Protocol 1VIT08021: A multi-center, randomized controlled study to investigate the safety and tolerability of a single dose of intravenous ferric carboxymaltose (FCM) vs. standard medical care in treating iron deficiency anemia in subjects who are not dialysis dependent (2010)

Principal Investigator-Roche NA22823: A Phase II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab (TCZ) versus placebo in patients with ankylosing spondylitis (AS) who have failed non-steroidal anti-inflammatory drugs and are naive to TNF antagonist therapy (2010)

Principal Investigator-Roche WA22908: A randomized, double-blind, parallel-group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylosing spondylitis who have had an inadequate response to previous TNF antagonist therapy (2010)

Principal Investigator-Teva LA-LAQ-202: A phase IIa, Multicenter, Randomized, Double blind, Placebo Controlled study to evaluate the safety, tolerability and clinical effect of Laquinimod in Systemic Lupus Erythematosus patients with active Lupus Arthritis (2010)

Principal Investigator-VQ OrthoCare Protocol VQ-B1000-01: Osteoarthritis of the Knee Registry for patients who have been prescribed the BionCare Knee System for use with the OActive Knee Brace for the FDA cleared indication "for use as an adjunctive therapy in reducing the level of pain and symptoms associated with osteoarthritis of the knee and for overall improvement of the knee as assessed by the Physician's Global Evaluation. (2010)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator—Cephalon Protocol CEP-33457/3075: An Open-Label Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients with Systemic Lupus Erythematosus (2010)

Principal Investigator—Cephalon Protocol CEP-33457/2047: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients with Systemic Lupus Erythematosus (2010)

Principal Investigator—Teva LN-LAQ-201: A phase IIa, Multicenter, Randomized, Double blind, Placebo Controlled study to evaluate the safety, tolerability and clinical effect of Laquinimod in Active Lupus Nephritis Patients, in combination with standard of care (Mycophenolate Mofetil and Steroids) (2010)

Principal Investigator—Takeda Protocol TMX-67_204: A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat versus Placebo in Joint Damage in Hyperuricemic Subjects with Early Gout (2010)

Principal Investigator—Bristol-Myers Squibb (BMS) Protocol IM101-235: A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept versus Subcutaneous Adalimumab, Both with Background Methotrexate, in Biologic-Naïve Subjects with Rheumatoid Arthritis. (2010)

Principal Investigator—UCB Protocol RA0056: A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study with an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects with Active Rheumatoid Arthritis Having Previously Failed TNF-Blocker Therapy (2010) ***High enrolling site**

Principal Investigator—Takeda Protocol TMX-67_301: A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities (2010) ***High enrolling site**

Principal Investigator—Lilly Protocol H9B-MC-BCDM: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy (2010)

Principal Investigator—MedImmune Protocol MI-CP 212: A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects with Systemic Lupus Erythematosus or Myositis (2010)

Sub-Investigator—AstraZeneca Protocol D4300C00003 (OSKIRA-3): A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Response to a TNF-alpha antagonist (2011)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator-Pfizer Protocol A3921129: A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis Receiving CP-690,550 or Placebo CP-690,550 with and with-out Background Methotrexate (2011)

Principal Investigator-Lilly H9B-MC-BCDS: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (2011)

Principal Investigator-Pfizer Protocol B0151006: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-04236921 in Subjects with Systemic Lupus Erythematosus (SLE) (2011)

Principal Investigator-Array Biopharma 797-223: A Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel-Arm, 4-Week Study to Investigate the Analgesic Efficacy and Safety of ARRY-371797 in Patients with Pain Due to Osteoarthritis of the Knee (2011)

Principal Investigator-Ardea Protocol ALLO-401: Long Term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) (2011)

Principal Investigator-UCB Protocol RA0057: A Phase II, Multi-Center, Open-Label, Follow-Up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis Who Completed Study RA0056 (2011)

Principal Investigator-Lilly Protocol H9B-MC-BCDV: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or More TNF-a Inhibitors (2011)

Principal Investigator-Lilly Protocol H9B-MC-BCDO: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) with or Without Background Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapy (2011) ***High enrolling site**

Sub-Investigator-Purdue Protocol ONU3701: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around-the-clock Opioid Therapy (2011)

Sub-Investigator-AstraZeneca Protocol D4300C00002 (OSKIRA-2): A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs (2011)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator–Roche Protocol MA25522: A Randomized, Double-Blind, Parallel-Group Study of the Reduction of Signs and Symptoms During Treatment with Tocilizumab Verses Adalimumab, Both in Combination with MTX, in Patients with Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment with Only One TNF Inhibitor (2011)

Principal Investigator–UCB Protocol RA0064: A Phase IV, Multicenter, Randomized, 52-Week Study to Evaluate the Routine Assessment of Patient Index Data (RAPID3) Compared to the Prospectively Predicted Treatment Success at 52 Weeks Based on a Treatment Decision at Week 12 in Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Certolizumab Pegol (CZP) (2011)

Principal Investigator–Genentech Protocol ML25641: A multicenter, open-label, single-arm study to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with rheumatoid arthritis (2011)

Principal Investigator–Amgen Protocol 20101218: Prospective Observational Study to Evaluate the Persistence with Prolia (Denosumab) in Postmenopausal Women with Osteoporosis in Routine Clinical Practice (2011)

Principal Investigator–Eli Lilly Protocol H9B-MC-BCDP: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) (2011)

Principal Investigator–Bristol-Myer Squibb Protocol IM133-004: A phase 2b, randomized, double-blind, placebo-controlled, dose ranging, multi-center study to evaluate the efficacy and safety of BMS-945429 subcutaneous injection in adults with active psoriatic arthritis (2011)

Sub-Investigator–AstraZeneca Protocol D4300C00005 (OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis (2011)

Principal Investigator–Bristol-Myers Squibb (BMS) Protocol IM133-001-065: Phase IIB, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate (2011)

Sub-Investigator–AstraZeneca Protocol D4300C00004 (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab Monotherapy in Patients with Active Rheumatoid Arthritis. (2011)

Principal Investigator–Novartis Protocol AIN457F2302: A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFα agents (2011) ***High enrolling site**

Principal Investigator-Novartis Protocol AIN457F2306: A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with psoriatic arthritis (2011) ***High enrolling site**

Principal Investigator-UCB Protocol SL0012: A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4) (2011) ***High enrolling site**

Principal Investigator-Human Genome Sciences (HGS) Protocol HGS1006-C1115: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE) (2011)

Principal Investigator-Roche/Genentech Protocol NV20234: A Double-Blind, Randomized, Stratified, Multi-Center Trial Evaluating Conventional and High Dose Oseltamivir in the Treatment of Immunocompromised Patients with Influenza (2011)

Principal Investigator-Pfizer Protocol A6261008: A Randomized, Subject and Investigator-Blinded (Sponsor-Open), Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Dose of PD 0360324 in Subjects with Active Cutaneous Lupus Erythematosus (CLE) (2012)

Principal Investigator-Amgen Protocol 20110166: A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy if AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis (2012)

Principal Investigator-GSK Protocol HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease (2012)

Principal Investigator-Janssen Protocol 38518168ARA2002: A Phase 2b Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-group, Dose Range Finding Study or JNJ-38518168 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy (2012)

Principal Investigator-Bristol-Myers Squibb (BMS) Protocol MB102-073-0570: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliglozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) (2012)

Principal Investigator-UCB Protocol SL0009: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 weeks total) of Epratuzumab in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease (2012) ***High Enrolling site**

CURRICULUM VITAE

Emily Jane Box, MD

Principal Investigator-Bristol-Myers Squibb (BMS) Protocol MB102-077-0519: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication (2012)

Principal Investigator-Novo Nordisk Protocol NN8226-3612: A Randomised, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, and Anti-IL-20 Biologic, in Patients with Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNF α Biologics (2012)

Principal Investigator-Novo Nordisk Protocol NN933-3613: A randomized, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to Methotrexate (2012)

Principal Investigator-Boehringer Ingelheim Protocol 1301.1: Efficacy, Pharmacokinetics, and Safety of BI 695500 versus Rituximab in Patients with Moderately to Severely Active Rheumatoid Arthritis: A Randomized, Double-Blind, Parallel Arm, Multiple Dose, Active Comparator Trial. (2012)

Principal Investigator-Forest Research Protocol LAS-MD-45: Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Aclidinium Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (2012)

Principal Investigator-Human Genome Sciences (HGS) Protocol HGS1006-C1112: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-week Study to Evaluate the Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE) (2012)

Principal Investigator-BMS Protocol IM133001: A Phase IIB, Randomized, Multicenter, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection with or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate (2012)

Principal Investigator-Genentech Protocol NA25256: A Randomized, Parallel-Group, Open-Label, Multicenter Study to Evaluate the Effects of Tocilizumab on Vaccination in Subjects with Active Rheumatoid Arthritis Receiving Background Methotrexate (2012)

Principal Investigator-Janssen Research & Development Protocol CNTO136ARA3002: AS Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite DMARD Therapy (2012)

Principal Investigator-Eli Lilly Protocol H9B-MC-BCDX: A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (2012)

Principal Investigator-Janssen Research & Development Protocol CNTO136ARA3003: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with active Rheumatoid Arthritis Despite Anti-TNF α Therapy (2012)

Principal Investigator-Janssen Research & Development Protocol CNTO136ARA3004: A Multicenter, Parallel-Group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) in Rheumatoid Arthritis Subjects Completing Treatment in CNTO136ARA3002 and CNTO136ARA3003 (2012)

Sub-investigator-AstraZeneca Protocol D4300C00033 (OSKIRA-ABPM): A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis (2012)

Principal Investigator-Vertex Protocol VX-11-509-102: A 24-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Subjects with Active Rheumatoid Arthritis on Stable Methotrexate Therapy with 104-Week Open Label Extension (2012)

Principal Investigator-ARDEA Protocol AIR-302: A Phase 3 Randomized, Double-blind, Multi-center, placebo-controlled, combination study to evaluate the efficacy and safety of lesinurad and allopurinol compared to allopurinol alone in subjects with gout who have had inadequate hypouricemic response to standard of care allopurinol. (2012)

Principal Investigator-Amgen Protocol 20110232: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn's Disease (2012)

Principal Investigator-Pfizer Protocol B3281001: A Randomized, Double-Blind, Study Comparing the Pharmacokinetics and Pharmacodynamics, and Assessing the Safety of PF-05280586 and Rituximab in Subjects with Active Rheumatoid Arthritis on a Background of Methotrexate Who Have had an Inadequate Response to One or More TNF Antagonist Therapies (2012)

Principal Investigator-Pfizer Protocol B3281004: Extension Study Evaluating Treatment with PF-05280586 Versus Rituximab in Subjects with Active Rheumatoid Arthritis who have Participated in Other PF-05280586 Clinical Trials (2012)

Principal Investigator-Bristol-Myers Squibb Protocol IM133-005: A Phase IIb Double-blind, Randomized, Placebo-controlled, double-dummy, dose ranging study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subjects with moderate to severe Crohn's disease (2012)

Principal Investigator-Amgen Protocol 20120103: A phase 3 Study to Evaluate the Safety and Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in subjects with moderate to severe Plaque Psoriasis: AMAGINE-2 (2012)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator- Amgen Protocol 20120125: A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment with Adalimumab When Used as Their First Biologic Agent (2013)

Principal Investigator-ARDEA Protocol RDEA3170-201: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects with Gout (2013)

Principal Investigator-Eli Lilly Protocol I1F-MC-RHAO: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylosing Spondylitis I1F-MC-RHAO (2013)

Principal Investigator-Bristol-Myers Squibb Protocol IM101-366: Phase Ib, Multicenter, Randomized, Open Label, Parallel Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe (2013)

Principal Investigator-Boehringer Ingelheim Pharmaceuticals Protocol 1218.22-A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcome with LINagliptin, 5 mg once daily in patient s with type 2 diabetes mellitus at high vascular risk (CARMELINA) (2013)

Principal Investigator-Boehringer Ingelheim Protocol 1301.4: Safety and efficacy of BI 695500 in Patients with Moderately to Severely Active Rheumatoid Arthritis: An Open-Label Extension Trial (2013)

Principal Investigator-Ardea Protocol RDEA594-306: A Long-Term Extension Study of Lesinurad in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol (2013)

Principal Investigator-Bristol-Myers Squibb (BMS) Protocol IM101-332: A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis (2013) ***High enrolling site**

Principal Investigator-Intarcia Therapeutics Protocol ITCA-650-CLP-103: A Phase 3, Randomize, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes (2013)

Principal Investigator-Intarcia Therapeutics Protocol ITCA 650-CLP-103: Sub-Study-An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes with High Baseline HbA1c (2013)

Principal Investigator-Intarcia Therapeutics Protocol ITCA 650-CLP-107: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes (2013)

Principal Investigator-Merck Protocol MK-8808-002-02-0107: A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 with Rituximab (MabThera and Rituxan) in Patients with Rheumatoid Arthritis (RA) (2013)

Principal Investigator-Eli Lilly Protocol I1F-MC-RHAP: A Multicenter Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease- Modifying Antirheumatic Drug-Naïve Patients with Active Psoriatic Arthritis (2013)

Principal Investigator-Takeda Protocol TAK-875_303: A Randomized, Double-Blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared to Placebo Ehen Used in Combination with Sitagliptin in Subjects with Type 2 Diabetes (2013)

Principal Investigator-Eli Lilly Protocol H9B-MC-BCEI: Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto-Injector in Patients with Systemic Lupus Erythematosus (2013)

Principal Investigator-EMD Serono Protocol EMR-700461-023: A phase IIb, multi-center, randomized, double-blind, placebo-controlled, multidose, 24-week study to evaluate the efficacy and safety of Atacicept in subject with Systemic Lupus Erythematosus (SLE) (2013)

Principal Investigator-Mesoblast Protocol MSB-RA001: A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation, Multi-Center Study of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients with Rheumatoid Arthritis and Incomplete Response to at Least One TNF α inhibitor (2013)

Principal Investigator-Novartis Pharmaceuticals Protocol AIN457F2312: A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients with Active Psoriatic Arthritis (2013)

Principal Investigator-Novartis Pharmaceuticals Protocol AIN457F2302E1: A Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Subjects with Active Rheumatoid Arthritis (2013)

Principal Investigator-Regeneron Pharmaceuticals Protocol 6R88-RA-1309: A Multicenter, Open-Label, Randomized, Single-Dose Study Assessing the Pharmacodynamic Parameters of IL 6 Receptor Blockade with Sarilumab or Tocilizumab in Patients with Rheumatoid Arthritis on Stable Methotrexate Treatment 6R88-RA-1309 (2013)

Principal Investigator-Novartis Pharmaceuticals Protocol AIN457F2306E1: A Three-Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients with active Psoriatic Arthritis (2013)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator-Novartis Pharmaceuticals Protocol AIN457F2312: A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients with Active Psoriatic Arthritis (2013)

Principal Investigator-Questcor Pharmaceuticals Protocol QSC01-SLE-01: A Two-Party Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients with a History of Persistently Active Disease (2013)

Principal Investigator-EMD Serono Protocol EMR700461-024: A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects with Systemic Lupus Erythematosus (SLE) who Completed Protocol EMR-700461-023 (ADDRESS II) (2014)

Principal Investigator-Sandoz Protocol GPN013A2301: A randomized, double-blind, controlled study to evaluate the pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and Rituximab in patients with rheumatoid arthritis refractory or intolerant to standard DMARDs and one or up to three anti-TNF therapies (2014)

Principal Investigator-Santarus Protocol C2013-0302: A Randomized, Double-Blind, Placebo-Controlled, multiple Ascending Dose study to Evaluate the Safety Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease Modifying Anti-rheumatic Drugs (2014) ***High enrolling site**

Principal Investigator-CymaBay Therapeutics Protocol CB102-21425: A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients (2014)

Principal Investigator-Abbvie Protocol M12-963: A Phase 2 Study to Investigate the Safety and efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (2014)

Principal Investigator-Abbvie Protocol M13-538: Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) with ABT-494 (2014)

Principal Investigator-Abbvie M13-550: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given with Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Therapy (2014)

Principal Investigator-Celgene Protocol CC-220-SLE-001: A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-220 in Subjects with Systemic Lupus Erythematosus (2014)

Principal Investigator-Celgene Protocol CC-292-RA-001: A Phase 2a, 4-Week Double-Blind, Proof-Of-Concept Efficacy and Safety Study of CC-292 versus Placebo as Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (2014)

Principal Investigator-Coherus Protocol CHS-0214-02: A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 versus Enbrel in Subjects with Rheumatoid Arthritis and Inadequate Response to Treatment with Methotrexate (2014)

Principal Investigator-Coherus Protocol CHS-0214-04: A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS0214 versus Enbrel in Subjects with Chronic Plaque Psoriasis (2014)

Principal Investigator-Daiichi Sankyo Development Protocol DS556-A-E309: A Randomized Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia (2014)

Principal Investigator-Daiichi Sankyo Development Protocol DS5565-A-E312: An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia (2014)

Principal Investigator-GSK Protocol 200339: An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector that Administers Belimumab Subcutaneously in Subject with Systemic Lupus Erythematosus (SLE) (2014)

Principal Investigator-Incyte Corporation Protocol INCB 47986-202: A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects with Active Rheumatoid Arthritis (2014)

Sub-Investigator-Pfizer Protocol B1801364: Anti-TNF Antibody-Mediated Blockade of Drug Efficacy in Rheumatoid Arthritis (ANTIBODY_RA) (2014)

Principal Investigator-AstraZeneca Protocol D3461C00005: A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study evaluating the efficacy and safety of SLE biologic product in adults subjects with active systemic lupus erythematosus (2015)

Principal Investigator-Lilly Protocol I1F-MC-RHBE: A multicenter, randomized, double-blind, placebo-controlled 24-week study followed by long-term evaluation of efficacy and safety of Ixekizumab (LY2439821) in biologic disease-modifying antirheumatic drug-experienced patients with active psoriatic arthritis (2015)

Principal Investigator-Acerta Protocol ACE-RA-001: A phase 2a, 4-week, double-blind, proof-of-concept efficacy and safety study of ACP-196 versus placebo in subjects with active rheumatoid arthritis on background methotrexate (2015)

CURRICULUM VITAE

Emily Jane Box, MD

Principal Investigator-Coherus Protocol CHS-1420-02: A double-blind, randomized, parallel-group, active-control study to compare the efficacy and safety of CHS-1420 drug product versus Humira in subjects with chronic plaque psoriasis (2015)

Principal Investigator- Regeneron Protocol R475-PN-1227: A randomized, double-blind, parallel-group, dose-ranging study of the efficacy and safety of R475 in patients with osteoarthritis of the knee/hip who have an inadequate response to NSAID and Opioid therapy (2015)

Principal Investigator-Sanofi Protocol EFC 14092: A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis (2015)

Principal Investigator- Abbvie Protocol M14-197: A phase 2 study to investigate the safety, tolerability and efficacy of ABT-122 in subjects with active psoriatic arthritis who have an inadequate response to methotrexate (2015)

Principal Investigator-Boehringer Ingelheim Protocol 1297.2: Efficacy, Safety and Immunogenicity of BI 695501 versus Adalumumab in Patients with Active Rheumatoid Arthritis: a Randomized, Double-Blind, Parallel Arm, Multiple Dose, Active Comparator Trial (2015)

Principal Investigator- Abbvie Protocol M14-465: A Phase 3, Randomized, Double-Blinded Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) (2015) ***High Enrolling site**

Principal Investigator- Ablynx NV Protocol ALX0061-C204: A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus (2015) ***High Enrolling site**

Principal Investigator-Seattle Genetics, Inc. Protocol SGN35-022: A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults with Active Systemic Lupus Erythematosus (2015)

Principal Investigator-UCB Biosciences, Inc. Protocol AS0006: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects with Active Axial Spondyloarthritis (AXSPA) without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation (2015)

Principal Investigator-Xencor XmAb5871-04: A randomized, double-blind, placebo-controlled study of the effect of XmAb5871 on systemic lupus erythematosus disease activity (2016) ***High Enrolling site**

Principal Investigator-ImmuPharma IPP-201101/005: A 52-week, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with systemic lupus erythematosus (2016)

Principal Investigator – Resolve Therapeutics Protocol: 132-03. A Phase IIA, Double Blind, Placebo Controlled Study of RSLV-132 In Subjects with SLE (2016)

Principal Investigator – Boehringer Ingelheim Pharmaceuticals, Inc. Protocol: 1311.4. BI 655066 verses placebo in a Multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment. (2016)

Principal Investigator – Abbvie Protocol M13-542. A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severe Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) (2016)

Principal Investigator – Sandoz Protocol: GP15-301. A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and Immunogenicity of GP2015 and Enbrel® (EU-authorized) in patients with moderate to severe, active rheumatoid arthritis (2016)

Principal Investigator – Mallinckrodt Protocol MNK14294063: A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease. (2016)

Principal Investigator – Mallinckrodt Protocol MNK14304067: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids. (2016)

Principal Investigator – Amgen Protocol 20140111: A Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis. (2016)

Principal Investigator – AstraZeneca Protocol D3461C00009: A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus. (2016)

Principal Investigator – Amgen Protocol 20130108: A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP798 with Rituximab in Subjects with Moderate to Severe Rheumatoid Arthritis. (2016)

Principal Investigator – Neovacs Protocol IFN-K-002: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Systemic Lupus Erythematosus. (2016)

Principal Investigator – Samumed Protocol SMO4690: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects. (2017)

CURRICULUM VITAE

Emily Jane Box, MD

Principal Investigator – Sobi Protocol Sobi.ANAKIN-401: A randomized, double-blind, active-control, multicenter, efficacy and safety study of 2 dose levels of subcutaneous anakinra compound to intramuscular tiamcinolone in the treatment of acute gouty arthritis, followed by a one-year extension. (2017)

Principal Investigator – Abbvie Protocol M15-554: A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) – SELECT – PsA 2. (2017)

Principal Investigator – Aurinia Protocol AUR-VCS-2016-01: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis. (2017)

Principal Investigator - Celgene Protocol CC-220-SLE-002: A Phase 2, multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of CC-220 in subjects with active Systemic Lupus Erythematosus. (2017)

Principal Investigator – Gilead Protocol GS-US-436-1092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Adult Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE). (2017)

Principal Investigator – Regeneron Protocol R475-OA-1611: R475-OA-1611: A Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasimumab in Patients with Pain due to Osteoarthritis (OA) of the Knee or Hip. (2017)

Principal Investigator – Abbvie Protocol M16-098: A Phase 2B/3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis (2017)

Principal Investigator – Ironwood Protocol EDEA594-401: EXPLORE Study: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance 30 to <60 mL/min Who Have Not Achieved Target Serum Uric Acid Levels on an XOI alone. (2017)

Sub-Investigator – Abbvie Protocol M16-283: A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women (2017)

Sub-Investigator- Myovant Protocol MVT-601-3101: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain (2017)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator – Abbvie Protocol M15-572: A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1 (2017)

Sub-Investigator – Cutanea Life Sciences, Inc Protocol CLS006-CO-PR-002: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)

Principal Investigator – Janssen Protocol CNT01275SLE3001: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus (SLE). 2018

Principal Investigator – Eli Lilly Protocol I4V-MC-JAIA: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus. 2018

Principal Investigator – Abbvie Protocol M16-063: A Phase 2 Proof of Concept Study to Investigate the Safety and Efficacy of ABBV-105 given alone or in combination with upadacitinib (ABBV-599) with a Background of csDMARDs in Subjects with Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs). 2018

Principal Investigator – BMS Protocol IM011084: A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA)

Principal Investigator – Selecta Protocol SEL-212/202: A Phase 2 Head-to-Head Study to Determine the Superiority of SEL-212 Over KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy.

Principal Investigator – UCB: A Phase 3, Multi-center, randomized, double-blind, placebo-controlled, active-reference study evaluating the efficacy and safety of Bimekizumab in the treatment of subjects with active Psoriatic Arthritis.

Principal Investigator – UCB: A Multi-Center, Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Bimekizumab in the treatment of subjects with active Psoriatic Arthritis.

Sub-Investigator – AZTherapies Protocol AZT-001: A phase III safety and efficacy study of AZT-OP1 in subjects with evidence of early Alzheimer's disease (2016)

Sub-Investigator – Abbvie Protocol M16-702: A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain. (2017)

Sub-Investigator – Cutanea Life Sciences, Inc Protocol CLS006-CO-PR-002: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 in Subjects 2 years of age or older with Cutaneous Common Warts (2017)

CURRICULUM VITAE

Emily Jane Box, MD

Principal Investigator – Amgen: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy

Principal Investigator – Eli Lilly: A Phase 1, Randomized, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3361237 in Patients with Systemic Lupus Erythematosus

Principal Investigator – Eli Lilly: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE). 2019

Sub-Investigator – Schipfer: Prospective Trial to Assess Clinical Utility of PrismRA to Predict Non-Responders to anti-TNF Therapies (NETWORK-001)

Principal Investigator – Sandoz: A randomized, double-blind, multicenter integrated phase I/III study in postmenopausal women with osteoporosis to compare the pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity of GP2411 (proposed biosimilar denosumab) and Prolia® (EU-authorized) 2019

Sub-Investigator – Astellas: Skylight 2: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause (2019)

Sub-Investigator – Astellas: Skylight 4: A Randomized, Placebo-Controlled, Double-Blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated with Menopause (2019)

Principal Investigator – UCB: A multicenter, open-label extension study to assess the long-term safety, tolerability, and efficacy of Bimekizumab in the treatment of subjects with active psoriatic arthritis. 2020

Principal Investigator – UCB: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy & Safety of DZP in Study Participants with Moderately to Severely Active SLE. 2020

Principal Investigator – Viela: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients with Rheumatoid Arthritis (RA)(short title: MIDORA). 2020

Sub-Investigator – DJL Clinical Research: Outpatient Treatment on COVID-19. 2020

Sub-Investigator – Dr Reddys Laboratories: A randomized, double-blind, parallel group, multicenter study to assess the immunogenicity and safety of transitioning subjects with rheumatoid arthritis to biosimilar rituximab (DRL_RI) or continued treatment with Rituxan® or MabThera® 2020

Principal Investigator – Idorsia Pharmaceuticals: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE). CARE: Cenerimod Assessing S1P1 Receptor modulation in Systemic Lupus Erythematosus

Principal Investigator – Amgen: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy

Principal Investigator – Sanofi: Randomized, double-blind, placebo controlled, multicenter proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus

Principal Investigator – Viela: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of moderate to severely active Systemic Lupus Erythematosus

Principal Investigator – Setpoint: A Randomized, Sham-Controlled, Double-Blind Study of Vagus Nerve Stimulation for Moderate-to-Severe Rheumatoid Arthritis: The RESET-RA Study

Principal Investigator – Biogen: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Principal Investigator – UCB: A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants with Systemic Lupus Erythematosus.

Principal Investigator – Gilead: A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects with Cutaneous Lupus Erythematosus (CLE)

Principal Investigator – Abbvie: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of an Investigational Drug in Subjects with Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Targeted Immunomodulators (b/tsDMARDs)

Principal Investigator – Janssen: Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Nipocalimab in active Rheumatoid Arthritis patients.

Principal Investigator – Janssen: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Participants with Active Systemic Lupus Erythematosus

Principal Investigator – BMS: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus

Principal Investigator – Nimbus Therapeutics: A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple -Dose Study to evaluate the efficacy, safety, and tolerability of NDI-034858 in SUBJECTS with active Psoriatic arthritis

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator – Horizon: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus

Sub-Investigator – Janssen: A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease

Sub-Investigator – Janssen: A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis

Principal Investigator – Biogen: A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus

Sub-Investigator – Janssen: A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease

Sub-Investigator – Janssen: A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis

Principal Investigator – Horizon: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus

Principal Investigator – Aclaris Therapeutics: Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with Moderate-to-Severe Active Psoriatic Arthritis

Principal Investigator – UCB: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (SL0044)

Principal Investigator – Idorsia: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic lupus erythematosus (SLE)

Principal Investigator – Eli Lilly: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis (KDAF)

CURRICULUM VITAE
Emily Jane Box, MD

Principal Investigator – F. Hoffmann-La Roche: A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutizumab in Patients with Systemic Lupus Erythematosus

Principal Investigator – Sanofi: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults with Moderate-to-Severe Rheumatoid Arthritis

Principal Investigator – Abbvie: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus (SLE) (699)

Principal Investigator – Alumis: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus

Principal Investigator – Galapagos: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus

Principal Investigator – Merck: A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus

DJL Clinical Research Investigative Site Network Consultant:

Novartis Protocol FTY720D2405: TRANSITION: A Two-Year Observational Study to Evaluate the Safety Profile of Fingolimod in Patients with Multiple Sclerosis who Switch from Natalizumab to Fingolimod (2014)

Novartis Protocol FTY720D2403: Long-Term, Prospective, Multinational, Parallel-Cohort Study Monitoring Safety in Patients with MS newly Started with Fingolimod Once Daily or Treated with Another Approved Disease-Modifying Therapy (2014)

Allergan Protocol GMA-BTX-SP-12-001: Adult SPasticity International Registry on BOTOX Treatment (ASPIRE) (2014)

Biogen Idec MA Protocol 218MS305: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE) (2014)

Roxane Protocol FLSA-P100/50-PCVL: A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma (2014)

Evidera Protocol EVA-14319-00: Assessing the Adequacy of Respiratory Patient-Reported Outcome (PRO) Instruments for Patients with Severe Eosinophilic Asthma (2015)

CURRICULUM VITAE

Emily Jane Box, MD

Baxalta US, Inc. Protocol #161406: Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) (2015)

AstraZeneca D2210C00008 Tralo: A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on an Inhaled Corticosteroid Plus Long-acting β 2-Agonist(2015)

Lilly Protocol I5Q-MC-CGAG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine-the EVOLVE-1 Study (2015)

Novartis Protocol CLEE011A2404: An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor–Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer With No Prior Hormonal Therapy for Advanced Disease (NCT02941926). (2017)

Foamix Protocol FX2017-22: A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris. (2017)

Pfizer Madeline Protocol A5481074: Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer (2017)

Merrimack SHERBOC/ MM121-02-02-10 Protocol: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy. (2017)

Pfizer Javelin Protocol B9991016: A Randomized, Double-Blind, Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (2018)

Ipsen protocol A-US-52030-358: Lanreotide and Octreotide LAR for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis. 2018

ARMO Biosciences AM0010-201 Cypress 1 Protocol: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression. 2018

Veloce Biopharma 2017-VBP-926 Protocol: A Multi-centered, Randomized, Double-Blind, Vehicle-Controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of Topical Povidone-Iodine Nail Solution (VBP-926) for the Treatment of Chemotherapy-Associated Paronychia in Cancer Patients (NCT03207906). 2018

CURRICULUM VITAE
Emily Jane Box, MD

Adamas Protocol ADS-AMT-MS301: A 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment. 2018

Incyte protocol INCB 54828-202: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. 2018

Amgen Protocol 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN. 2018

Amgen Protocol 20170596: An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers. 2019

BI Protocol 1280.22: XENERA™-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease. 2019

Vanda Protocol VP-VLY-686-3101: A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis. 2019

Adamas Protocol ADS-AMT-MS303: A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients with Multiple Sclerosis and Walking Impairment. 2019

Chemocentryx Protocol CL016_168: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. 2019

Skintech Protocol CRC375: A Randomized, Double Blind, Phase 2, Comparative 16-Week Study of ACCUMAX SUBLINGUAL (Diindolylmethane, DIM + Vitamin A) and Quercetin vs Placebo in Participants with Moderate to Severe Acne Vulgaris. 2019

Eli Lilly Protocol I4V-MC-JAIR: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata. BRAVE-AA2. 2019

Biohaven Protocol BHV3000-305: A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention. 2019

Trevi Therapeutics: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)

CURRICULUM VITAE
Emily Jane Box, MD

Regeneron: A Prospective Observational Study of Patients Receiving DUPIXENT® for Atopic Dermatitis

Regeneron: Cemiplimab Survivorship Epidemiology (CASE) Study

Vanda: A randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis (3102)

Abbvie: A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis. 2019

Astrazeneca: An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment. 2019

Incyte: Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). 2019

Sanofi: Master protocol of two randomized, double-blind, placebo-controlled, multi-center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in two populations - Study A in patients naïve to omalizumab and Study B in patients who are incomplete responders to omalizumab.

Astrazeneca: A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Concert Pharmaceuticals: A Double-blind, Randomized, Placebo-controlled study to evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Novartis: Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multicenter Phase IIb study (EXCHANGE)

Lilly: preventive Treatment of migraine: outcomes for Patients in real-world Healthcare systems (TRIUMPH).

BMS: GUARD-AF: reducing stroke by screening for Undiagnosed atrial fibrillation in elderly individuals – Syneos Health.

GSK: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer.

Abbvie: A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications. (PROSPECT)

Novocure: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer (KEYNOTE)

Fibrogen: A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)

GW Pharma: A Randomized Double-Blind Placebo-Controlled Study of Nabiximols in Patients with Spasticity in Multiple Sclerosis

Incyte: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Cerevel Therapeutics: 58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)

Concert: A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Concert: A Multicenter, Open-label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata

Abbvie: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects with Moderate to Severe Psoriasis.

AnaptysBio: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnimab (ANB030) in the Treatment of Subjects with Moderate to Severe Alopecia Areata

Janssen: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis

UBC: Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

BMS/Labcorp: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Myovant: A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX®

Regeneron: A Phase 1/2 Study Of Cemiplimab (Anti-PD-1 Antibody) In Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy In First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 $\geq 50\%$

CURRICULUM VITAE

Emily Jane Box, MD

Novartis: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Verses Teriflunomide in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-Label Remibrutinib

Amgen: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)

Atreca: A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies

Eli Lilly: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children from 6 Years to less than 18 Years of Age with Alopecia Areata

Myovant: Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)

Aslan Pharmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab

AnaptysBio: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

Abbvie: A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis (702)

Astellas: A Phase IV, Longitudinal, Observational Study Examining Real World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothering Vasomotor Symptoms

Intra-Cellular Therapies: A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson's Disease

Janssen: A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Guselkumab Versus Placebo for the Treatment of Low BSA Moderate Plaque Psoriasis With Special Site Involvement

Eli Lilly: A Phase 2b, Double Blind, Placebo Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa


Pfizer: A Phase 3 Randomized, Double-Blind, 52-Week Placebo-Controlled Multi-Center Study with A Double-Blind 52-Week Extension Period with Randomized Dose Up/Dose Down Titration Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Adult Participants with Nonsegmental Vitiligo

CURRICULUM VITAE
Emily Jane Box, MD

UCB: A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants with Advanced Parkinson's Disease

WEX Pharmaceuticals: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy-Induced Neuropathic Pain

My signature verifies the information in this document is accurate and updated appropriately.


Signature

06/25/2024
Date